EASL2020：最新肝病領域「重磅研究」概覽！

2020年8月27～29日，第55屆歐洲肝臟研究學會年會（EASL2020）暨國際肝臟會議（TheDigitalInternationalLiverCongress?2020，ILC2020）將在歐洲最大的城市——英國·倫敦盛大召開。

既往歐洲國際肝病大會現場都會匯集來自世界各地的專家，借此了解肝臟研究的最新進展。與以往不同的是，鑒于COVID-19大流行的影響，今年大會完全改為線上舉行。

今年大會共收集了來自55個國家專家學者的研究摘要，其中1470+多篇原創研究成果將在壁報和視頻展示。依照慣例，今年篩選出8項最新突破研究和13項重磅研究分別在最新突破專題（LateBreaker）和全體大會（Generalsession）由團隊代表進行口頭報告。重磅研究見下：

GS01苯扎貝特（Bezafibrate）聯合治療可提高原發性膽管炎無肝移植患者的存活率：一項日本全國性隊列研究

GS01Bezafibrateadd-ontherapyimproveslivertransplantation-freesurvivalinpatientswithprimarybiliarycholangitis:aJapanesenationwidecohortstudy

AtsushiTanaka,JapanCo-author:ChristopheCorpechot

27August202013:15-13:30

GS02糞便亞基因組中的毒性相關基因與酒精性肝炎患者死亡率相關

GS02Virulence-relatedgenesinfaecalmetagenomesassociatedwithmortalityinpatientswithalcoholichepatitis

SonjaLang,UnitedStatesCo-author:BerndSchnabl

27August202013:30-13:45

GS03端粒相關基因突變患者的肝臟受累：患病率、臨床、影像學、病理學特征、轉歸和危險因素

GS03Liverinvolvementinpatientswithtelomere-relatedgenesmutations:prevalence,clinical,radiological,pathologicalfeatures,outcomeandriskfactors

SabrinaSIDALI,FranceCo-author:AuréliePlessier

27August202013:45-14:00

GS04腸道微生物群通過促進TLR4依賴的單核細胞髓源性抑制細胞的增殖來促進肝癌發生

GS04GutmicrobiotadriveshepatocarcinogenesisbypromotingTLR4-dependentexpansionofmonocyticmyeloid-derivedsuppressorcells

KaiMarkusSchneider,GermanyCo-author:AntjeMohs

27August202014:00-14:15

GS05歐洲國家器官儲運組織終末期肝病鈉評分的模型驗證

GS05ValidationoftheModelforEnd-stageLiverDiseasesodiumscorefortheEurotransplantregion.

BenGoudsmit,NetherlandsCo-author:BartVanHoek

27August202014:15-14:30

GS06一項隨機、多中心、雙盲、安慰劑對照試驗：左旋肉堿對肝硬化患者和隱性肝性腦病患者生活質量的影響

GS06Arandomised,multi-centre,double-blinded,placebocontrolled,investigator-initiatedtrialtoassesstheimpactofL-carnitineadministrationonqualityoflifeincirrhosispatientsandcoverthepaticencephalopathy

EileenYoon,Korea,Rep.ofSouth

27August202014:30-14:45

GS07Nidufexor，一種非膽汁酸FXR激動劑，在給藥12周后降低NASH患者的ALT水平和肝脂肪分數

GS07Nidufexor,anon-bileacidFXRagonist,decreasesALTandhepaticfatfractioninpatientswithNASHafter12weeksdosing

RichardAspinall,UnitedKingdomCo-author:MichaelBadman

27August202014:45-15:00

GS08在初級保健中引入"reflex"AST檢測可提高晚期肝病的檢出率：TheGwentASTProject（GAP）

GS08Introductionof"reflex"ASTtestinginprimarycareincreasesdetectionofadvancedliverdisease:TheGwentASTProject(GAP)

AndrewYeoman,UnitedKingdomCo-author:Dr.FidanYousuf

28August202013:30-13:45

GS09單酰甘油脂肪酶重組巨噬細胞和肝細胞的脂質代謝，促進肝再生

GS09Monoacylglycerollipasereprogrammeslipidmetabolisminmacrophagesandhepatocytestopromoteliverregeneration

ManonAllaire,FranceCo-author:HélèneGilgenkrantz

28August202013:45-14:00

GS10在接受核苷類似物治療的慢性乙型肝炎患者中，用RNA干擾療法（JNJ-3989）進行短期治療可持續抑制乙型肝炎表面抗原

GS10Short-termtreatmentwithRNAinterferencetherapy,JNJ-3989,resultsinsustainedhepatitisBsurfaceantigensuppressioninpatientswithchronichepatitisBreceivingnucleos(t)ideanaloguetreatment

EdwardGane,NewZealandCo-author:StephenLocarnini

28August202014:00-14:15

GS11巨噬細胞清道夫受體1介導肥胖相關非酒精性脂肪肝的脂質性炎癥反應

GS11MacrophageScavengerReceptor1mediateslipid-inducedinflammationinhumanobesity-relatednon-alcoholicfattyliverdisease

OlivierGovaere,UnitedKingdomCo-author:QuentinAnstee

28August202014:15-14:30

GS12自身免疫性肝炎肝移植術后患者和移植物的長期存活率

GS12Long-termpatientandgraftsurvivalafterlivertransplantationforautoimmunehepatitis

MelinaHeinemann,GermanyCo-author:ChristophSchramm

28August202014:30-14:45

GS13HCV消除后肝硬化患者血清常規參數和AFP演變的分析，用于HCC風險分層：來自ANRSCO12CirVir隊列的軌跡聚群分析

GS13ProfilingofRoutineserumparametersandAFPevolutionincirrhosisfollowingHCVeradicationforstratificationofHCCrisk:atrajectoryclusteringanalysisfromtheANRSCO12CirVircohort

PierreNahon,FranceCo-author:EtienneAudureau

28August202014:45-15:00

信源：ESAL官網